Behcet's disease: Global perspective

Indian Journal of Rheumatology

Volumn 2, Issue 2, 2007, Pages 65-71

  Davatchi, F ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Behcet's disease; Clinical manifestations; Diagnosis; Epidemiology; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC AGENT; ETANERCEPT; HLA B51 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEVAMISOLE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; APHTHOUS ULCER; BEHCET DISEASE; BLINDNESS; CHINA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM INJURY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; EPIDIDYMITIS; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; FLU LIKE SYNDROME; GERMANY; HEALTH SURVEY; HEMATURIA; HUMAN; IRAN; IRIDOCYCLITIS; JAPAN; KIDNEY DISEASE; KOREA; LEUKOCYTURIA; MONARTHRITIS; MONOTHERAPY; MORBIDITY; MOROCCO; MUCOSAL DISEASE; NEUROLOGIC DISEASE; ORCHITIS; PHLEBITIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; PUSTULOSIS; RETINA VASCULITIS; REVIEW; SEX DIFFERENCE; TURKEY (REPUBLIC); UNITED KINGDOM; UVEITIS;

EID: 84992236530     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(10)60040-4     Document Type: Review

References (28)

1. Shahram F, Nadji A, Jamshidi AR, Chams H, Chams C, Shafaie N, et al. Behcet's Disease in Iran, analysis of 5059 cases. Arch Iranian Med 2004; 7: 9-14.
2. Nakae K, Masaki F, Hashimoto T, Inaba G, Moshizuki M, Sakane T. Recent epidemiological features of Behcet's Disease in Japan. In: Godeau P, Wechsler B, editors. Behcet's Disease. Amsterdam: Elsevier, 1993, pp. 145-51.
3. Zhang Z, Peng J, Hou X, Dong Y. Clinical manifestations of Behcet's Disease in Chinese patients. APLAR J Rheumatol 2006; 9: 244-7.
4. Altenburg A, Papoutsis N, Orawa H, Martus P, Zouboulis CC. Epidemiologie und klinik des morbus adamantiades-Behçet in Deutschland - aktuelle pathogenetische konzepte und therapeutische Möglichkeiten. J Dtsch Dermatol Ges 2006; 4: 49-66.
5. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behcet's Disease: an analysis of 2147 patients. Yonsei Med J 1997; 38: 423-7.
6. Bang D, Yoon Ku, Chung HG, Choi EH, Lee ES, Lee S. Epidemiological and clinical features of Behcet's Disease in Korea. Yonsei Med J 1997; 38: 428-36.
7. Benamour S, Naji T, Echchilali K, Hamimouch S; Moudatir M, Alaoui FZ, et al. Study of 1034 cases of Behcet's Disease. 12th International Conference on Behcet's Disease 2006, Lisbon (Portugal), Abstract B2.
8. Seaman G, Pearce RA. Behcet's Disease manifestation in a population drawn from the UK Behcet's Syndrome Society. In: Hamza M, editor. Behcet's Disease, Tunisia, Pub Adhoua, 1997, pp. 196-9.
9. Jamshidi AR, Davatchi F, Tehrani Banihashemi A, Moradi M, Gholami J, Samadi F. Prevalence of Behcet's Disease in Iran: a WHO-ILAR COPCORD study, 12th International Conference on Behcet's Disease 2006, Lisbon (Portugal), Abstract B16.
10. Chams C, Mansoori P, Shahram F, Akbarian M, Gharibdoost F, Davatchi F. Iconography of muco cutaneous lesions of Behcet's Disease. In Godeau P, Wechsler B, editors. Behcet's Disease. Amsterdam: Elsevier, 1993, pp. 359-62.
11. Chams-Davatchi C, Davatchi F, Shahram F, Akbarian M, Gharibdoost F, Nadji A. Longitudinal study of the Pathergy phenomenon in Behcet's disease. Hamza M, editor. Behcet's Disease, Tunisia, Pub Adhoua, 1997, pp. 356-8.
12. Shahram F, Zafar-Mohatashami A, Nadji A, Akhlaghi M, Ziaie N, Davatchi F. Articular manifestations in Behcet's Disease - a review of 1716 cases. 12th International Conference on Behcet's Disease 2006, Lisbon (Portugal), Abstract B6.
13. Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro Behcet's Disease - a review. The Neurologist 2005; 11: 80-9.
14. Plotkin GR. Gastrointestinal features. In: Plotkin GR, Calabro JJ, O'Duffy JD, editors. Behcet's Disease: a Contemporary Synopsis. Mount Kisco, New York: Futura Publishing, 1988, pp. 239-99.
15. Shahram F, Eslami M, Shakoori B, Haydari M, Nadji A, Akbarian M, et al. Cardiac involvement in Behcet's Disease - a case control study. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing, 2000, pp. 810-4.
16. International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). Evaluation of the International Criteria for Behcet's Disease. 12th International Conference on Behcet's Disease 2006, Lisbon (Portugal), Abstract B4.
17. International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). Revision of the International Criteria for Behcet's Disease (ICBD). 12th International Conference on Behcet's Disease 2006, Lisbon (Portugal), Abstract B10.
18. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double blind trial of colchicine in Behcet's syndrome. Arthritis Rhem 2001; 44: 2686-92.
19. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Chams-Davatchi C, et al. Colchicine: double blind cross-over study in Behcet's Disease. 12th International Conference on Behcet's Disease 2006, Lisbon (Portugal), Abstract H3.
20. Davatchi F, Baygan F, Chams H, Chams C, Contractor M. Levamisole in Behcet's Disease. "R" 1984; 14: 109-13.
21. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neuropsychological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828-32.
22. Davatchi F, Shams H, Shahram F, Nadji A, Jamshidi AR, Akhlaghi M, et al. Management of ocular manifestations of Behcet's Disease; outcome with cytotoxic drugs. APLAR J Rheumatol 2005; 8: 119-23.
23. Davatchi F. New and innovative therapies for Behcet's Disease. APLAR J Rheumatol 2004; 7: 141-5.
24. Kotter I, Gunaydin I, Treush M, Zierhut M, Kanz L, Stubiger N. The use of interferon-α in Behcet's Disease: review of the literature. Semin Arthritis Rheum 2004; 33: 320-35.
25. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gous F, Yurdakul S, et al. Short-term trial of Etanercept in Behcet's Disease: a double blind placebo controlled study. J Rheumatol 2005; 32: 98-105.
26. Melikoglu M, Ozvazgan Y, Fresko I, et al. The response of treatment resistant uveitis in Behcet's syndrome (BS) to a TNF-α blocker, Etanercept: an open study. Arthritis Rheum 2002; 46: S181 [Abstract 400].
27. Ohno S, Nakamura S, Hori S, Shimakawa M, Kamashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's Disease with refractory uveroretinitis. J Rheumatol 2004; 31: 1241-3.
28. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kaspaoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's Disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-84.